Applied Molecular Transport Leadership

Doug Rich is the Chief Technical Officer at Applied Molecular Transport.Doug Rich attended Pepperdine Graziadio Business School.

Shawn joined AMT as chief financial officer in 2020 where he leads the company’s finance strategy and oversees financial operations. He brings over 20 years of biopharmaceutical strategic advisory and capital market experience. Prior to joining AMT, Mr. Cross was at JMP Securities where he served as managing director and co-head of healthcare investment banking. Previously, Shawn held various investment banking roles at top financial institutions in New York, London and San Francisco including managing director in healthcare investment banking at Deutsche Bank Securities, managing director and head of biopharmaceutical investment banking at Wells Fargo Securities, amongst others. He also brings operational experience from his time on the executive management team at GT Biopharma, a targeted immunotherapies company. Shawn holds an M.B.A. from Columbia Business School and a B.S. from the University of California, Los Angeles.

Bittoo leads Clinical Development activities at Applied Molecular Transport, where he is overseeing the current clinical program AMT-101 and developing clinical strategy for the company’s pipeline assets and technology platforms. Previously, Bittoo was VP of Clinical Development at Protagonist Therapeutics where he led programs in Ulcerative Colitis and Crohn’s Disease. He began his industry career at Gilead Sciences where he supported programs in liver fibrosis/NASH, Hepatitis B and C, and served as the Clinical Domain Lead for Inflammatory Bowel Disease. Prior to his career in industry, Bittoo was an adjunct associate professor at UCSF focused on researching the role of the gut adaptive immune response in both HIV infection and IBD. Bittoo obtained his MD from the University of Iowa, completed his residency at Rush University Hospitals in Chicago, and a fellowship in pediatric gastroenterology from UCSF.

Liz joined AMT to lead multiple business functions, including Corporate Development and Strategy, Alliance Management, Portfolio Strategy and Project Management, and Commercial Development. Liz brings more than twenty-five years of biotech and pharmaceutical company experience, including roles in corporate development, corporate strategy, and commercial strategy.

Liz most recently held the positions of Chief Operating Officer and Chief Business Officer at Achaogen where she led in-licensing, out-licensing and acquisitions, alliance management and government grants, in addition to holding operational responsibilities. Prior to Achaogen, Liz was VP, Corporate Development at Gilead Sciences where she was responsible for leading teams to execute licenses, acquisitions and collaborations across all of Gilead’s therapeutic areas, which included transactions for filgotinib (Galapagos), firsocostat (Nimbus) and Yescarta (Kite Pharma). During her time at Gilead, she also led long-term global commercial and strategic planning for Gilead’s HIV, HepB, HepC and respiratory franchises and supported the launch of several products. Liz also held corporate development and strategy roles at Eli Lilly and Maxygen and started her career in research at Affymax. Liz earned a BA in Chemistry from Pomona College, a MS in Biomedical Sciences from UC San Diego, and an MBA from the Kellogg School of Management at Northwestern University.